Close
Almac
Achema middle east

Clinerion continues expansion of Patient Network Explorer coverage in South America by partnering with B-TRIALS in Chile.

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.

Smarter Resource Planning for Complex Pharma Development Portfolios

Align limited resources with complex pharmaceutical portfolios through capacity forecasting, skills-based planning, and dynamic resource reallocation, improving execution outcomes without increasing costs or overburdening teams.

Aligning Scientific Innovation with Commercial Reality in Drug Development

The "Valley of Death" in pharma is no longer just about scientific failure; it is about commercial irrelevance. This article examines the critical need to align R&D ambition with market reality early in development. It explores the evolution of the Target Product Profile (TPP) into the Target Value Profile (TVP), the role of the "commercial scientist," and strategies for integrated evidence generation that satisfy both regulators and payers.
- Advertisement -

The Chilean company B-TRIALS, a specialist in providing tools and solutions in the health area, will be responsible for the expansion of Clinerion in Chile. This will give patients in Chile quicker and better access to innovative medical treatments via increased participation in clinical trials, and via accelerated product launch due to more efficient patient recruitment for clinical trials.

B-TRIALS, founded by pharmacists Pablo García and Ricardo Cuevas, offers a wide variety of services to the different stakeholders of clinical research, including multi-channel recruitment, clinical trial monitoring, clinical trial coordination, pharmaco vigilance, quality control, regulatory affairs, data management, etc.

Patient Network Explorer supports patient health by matching patients to trials conducted by clinical trial sponsors or researchers performing academic investigations.

“The implementation of the Clinerion’s Patient Network Explorer platform in hospitals and clinics, added to the quality of the specialist physicians in Chile, can lead the country to be a reference in clinical research and B-TRIALS will be the gear to make this happen,” says Pablo Garcia, Commercial Director of B-TRIALS.

“Chile is characterized by being a benchmark in quality and having the highest rate of studies per inhabitants in Latin America, as well as being one of the fastest growing economies in Latin America according to the World Bank. Sufficient reasons for Clinerion to have a presence in this country and bring our digital technology to the benefit of patients here,” says Ian Rentsch, CEO of Clinerion. “With its depth of innovativeness, wide expertise and excellent local connections, B-TRIALS will be an invaluable partner for us in establishing ourselves here.”

About Clinerion
Clinerion accelerates clinical research and medical access to treatments for patients. We use proprietary technologies for analysis of patient data from our global network of partner hospitals. Clinerion’s Patient Network Explorer radically improves the efficiency and effectiveness of clinical trial recruitment by offering data-driven protocol optimization, site feasibility evaluation and real-time patient search and identification to match patients to treatments. Our technology solution provides real-world evidence analytics for medical access. Clinerion facilitates the participation of partner hospitals in leading-edge, industry-sponsored trials and time savings in patient recruitment. We create innovative and disruptive fit-for-purpose solutions which enable pharmaceutical companies to shorten patient recruitment and save costs by streamlining operations and leveraging strategic intelligence. Clinerion’s proprietary Big Data analytics technologies leverage real-time data from electronic health records which comply with international patient privacy and data security regulations. Clinerion is a global data technology service company headquartered in Switzerland. Clinerion website: www.clinerion.com

Clinerion’s Patient Network Explorer: www.clinerion.com/index/OverviewOurSolutions/ClinerionPatientNetworkExplorer

About B-TRIALS
B-TRIALS is a fully independent, privately-owned company based in Santiago, Chile. The company has an expanding network of professionals specialized in the area of health and clinical research and has different business units: “I am a patient” a multi-channel recruitment platform, “B-TRIALS Solutions” oriented to the transportation of products at a controlled temperature and “B-TRIALS 360º” offering services such as CRO (Contract Research Organization) and SMO. B-TRIALS website: www.btrials.com

 

Latest stories

Related stories

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.

Smarter Resource Planning for Complex Pharma Development Portfolios

Align limited resources with complex pharmaceutical portfolios through capacity forecasting, skills-based planning, and dynamic resource reallocation, improving execution outcomes without increasing costs or overburdening teams.

Aligning Scientific Innovation with Commercial Reality in Drug Development

The "Valley of Death" in pharma is no longer just about scientific failure; it is about commercial irrelevance. This article examines the critical need to align R&D ambition with market reality early in development. It explores the evolution of the Target Product Profile (TPP) into the Target Value Profile (TVP), the role of the "commercial scientist," and strategies for integrated evidence generation that satisfy both regulators and payers.

AI-Crafted Pill Succeeds Trials of Plaque Psoriasis Patients

Takeda Pharmaceutical from Japan said on December 17, 2025,...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »